ArticleThe CRISPR journal2018
Enabling the Rise of a CRISPR World.
Article in The CRISPR journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Democratizing CRISPR? Legal complexity, access and the right to science.Nature biotechnology · 2026Article
- Application of CRISPR/Cas gene editing for infectious disease control in poultry.Open life sciences · 2025Review
- The Expanding Dissemination and Distribution Patterns of Diverse CRISPR Plasmids by Addgene.The CRISPR journal · 2023Article
- Governance Choices of Genome Editing Patents.Frontiers in political science · 2021Article
- Open Sharing During COVID-19: CRISPR-Based Detection Tools.The CRISPR journal · 2020Article
- The Promise of CRISPR for Human Germline Editing and the Perils of "Playing God".The CRISPR journal · 2020Article
- Genome editing using the endogenous type I CRISPR-Cas system inProceedings of the National Academy of Sciences of the United States of America · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CRISPR technology has dramatically changed scientists' ability to conduct research in medicine, biotechnology, and agriculture through faster, more efficient genome editing. A key driver of the technology's adoption is the easy, fast, and inexpensive access to vectors and the resulting next-generation tools by the nonprofit plasmid repository Addgene. Since 2013, Addgene has shipped over 100,000 CRISPR plasmids to more than 75 countries worldwide. This pipeline of new technologies is enabling cutting-edge research to address the grand challenges of mankind.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.